secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020539
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q1 net loss $16.8M; Celltrion partnership and FDA feedback on RT-102
--------------------------------------------------------------------------------

- Net loss of $16.8M for Q1 2023, up from $13.8M in Q1 2022; non-cash stock compensation $4.0M.
- Cash and equivalents $86.8M as of Mar 31, 2023; expected to fund operations to mid-2024.
- Announced partnership with Celltrion to develop RT-111, an oral ustekinumab biosimilar.
- FDA preliminary feedback supports 505(b)(2) pathway for RT-102 (osteoporosis); Phase 2 expected 2H 2023.
- Three Phase 1 studies expected in 2023: RT-111, RT-105 (adalimumab biosimilar), RT-110 (parathyroid hormone).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/0000950170-23-020539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/rani-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer